Palivizumab antibody | AbD23967
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using human anti palivizumab (clone AbD23967) at a concentration of 2 μg/ml followed by an HRP labeled anti-DYKDDDDK tag antibody in HISPEC diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with palivizumab, human IgG1/kappa, human IgG1/lambda, natalizumab, trastuzumab or tocilizumab at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using human anti palivizumab (clone AbD23967) titrated to the given concentrations in PBST, followed by an HRP labeled anti-His tag antibody in HISPEC diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data for binding to palivizumab is presented as the mean of three measurements
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®
Human anti Palivizumab
Anti-palivizumab antibody is a recombinant, neutralizing, anti-idiotypic antibody in monovalent Fab format; it is ideal for bioanalytical assays to measure levels of palivizumab and biosimilars. It is suitable as capture and detection antibody in a PK bridging ELISA format.
- Product Type
- Monoclonal Antibody
- Clone
- AbD23967
- Isotype
- HuCAL Fab monovalent
| Product Code | Applications | Datasheet | MSDS | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|---|
| HCA261 | E | 0.1 mg |
Human anti Palivizumab, clone AbD23967, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug palivizumab and inhibits it binding to its target. The antibody can be used to measure the levels of palivizumab and biosimilar products in bioanalytical assays.
Our anti palivizumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in monovalent Fab format, is recommended as the capture antibody, paired with the antibody in full immunoglobulin (Ig) format, clone AbD23967_hIgG1 (HCA262), as the detection antibody. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.
Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV.
View a summary of all anti-palivizumab antibodies
Our anti palivizumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in monovalent Fab format, is recommended as the capture antibody, paired with the antibody in full immunoglobulin (Ig) format, clone AbD23967_hIgG1 (HCA262), as the detection antibody. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.
Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV.
View a summary of all anti-palivizumab antibodies
Product Details
- Product Form
- A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL® phage display library, expressed in E. coli. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.
- Preparation
- Metal chelate affinity chromatography
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Palivizumab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD = 1.5 nM by real time, label free molecular interaction analysis on immobilized palivizumab.
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
His-tag is a registered trademark of EMD Biosciences. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Palivizumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in direct or indirect ELISA and in a PK bridging ELISA as a capture antibody together with the same antibody or HCA262P as the detection reagent.
Protocol: PK bridging ELISA to measure free drug
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Rat anti DYKDDDDK Tag:HRP | MCA4764P | 0.1 mg | E P WB | ||
| Mouse anti Penta Histidine Tag:HRP | MCA5995P | 125 µl | E WB |
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Human anti Palivizumab | HCA262 | 0.1 mg | E |
